Cargando…
Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial
BACKGROUND: Hemofiltration rate, changes in blood and ultrafiltration flow, and discrepancies between the prescribed and administered doses strongly influence pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents during continuous veno-venous hemofiltration (CVVH) in critically ill...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985915/ https://www.ncbi.nlm.nih.gov/pubmed/32010602 http://dx.doi.org/10.2478/jtim-2019-0031 |
_version_ | 1783491873167376384 |
---|---|
author | Breilh, Dominique Honore, Patrick M. De Bels, David Roberts, Jason A. Gordien, Jean Baptiste Fleureau, Catherine Dewitte, Antoine Coquin, Julien Rozé, Hadrien Perez, Paul Attou, Rachid Redant, Sebastien Kugener, Luc Saux, Marie-Claude Spapen, Herbert D. Ouattara, Alexandre Joannes-Boyau, Olivier |
author_facet | Breilh, Dominique Honore, Patrick M. De Bels, David Roberts, Jason A. Gordien, Jean Baptiste Fleureau, Catherine Dewitte, Antoine Coquin, Julien Rozé, Hadrien Perez, Paul Attou, Rachid Redant, Sebastien Kugener, Luc Saux, Marie-Claude Spapen, Herbert D. Ouattara, Alexandre Joannes-Boyau, Olivier |
author_sort | Breilh, Dominique |
collection | PubMed |
description | BACKGROUND: Hemofiltration rate, changes in blood and ultrafiltration flow, and discrepancies between the prescribed and administered doses strongly influence pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents during continuous veno-venous hemofiltration (CVVH) in critically ill patients. METHODS: Ancillary data were from the prospective multicenter IVOIRE (hIgh VOlume in Intensive caRE) study. High volume (HV, 70 mL/kg/h) was at random compared with standard volume (SV, 35 mL/kg/h) CVVH in septic shock patients with acute kidney injury (AKI). PK/PD parameters for all antimicrobial agents used in each patient were studied during five days. RESULTS: Antimicrobial treatment met efficacy targets for both percentage of time above the minimal inhibitory concentration and inhibitory quotient. A significant correlation was observed between the ultrafiltration flow and total systemic clearance (Spearman test: P < 0.005) and between CVVH clearance and drug elimination half-life (Spearman test: P < 0.005). All agents were easily filtered. Mean sieving coefficient ranged from 38.7% to 96.7%. Mean elimination half-life of all agents was significantly shorter during HV-CVVH (from 1.29 to 28.54 h) than during SV-CVVH (from 1.51 to 33.85 h) (P < 0.05). CONCLUSIONS: This study confirms that CVVH influences the PK/PD behavior of most antimicrobial agents. Antimicrobial elimination was directly correlated with convection rate. Current antimicrobial dose recommendations will expose patients to underdosing and increase the risk for treatment failure and development of resistance. Dose recommendations are proposed for some major antibiotic and antifungal treatments in patients receiving at least 25 mL/kg/h CVVH. |
format | Online Article Text |
id | pubmed-6985915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Sciendo |
record_format | MEDLINE/PubMed |
spelling | pubmed-69859152020-01-31 Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial Breilh, Dominique Honore, Patrick M. De Bels, David Roberts, Jason A. Gordien, Jean Baptiste Fleureau, Catherine Dewitte, Antoine Coquin, Julien Rozé, Hadrien Perez, Paul Attou, Rachid Redant, Sebastien Kugener, Luc Saux, Marie-Claude Spapen, Herbert D. Ouattara, Alexandre Joannes-Boyau, Olivier J Transl Int Med Original Article BACKGROUND: Hemofiltration rate, changes in blood and ultrafiltration flow, and discrepancies between the prescribed and administered doses strongly influence pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents during continuous veno-venous hemofiltration (CVVH) in critically ill patients. METHODS: Ancillary data were from the prospective multicenter IVOIRE (hIgh VOlume in Intensive caRE) study. High volume (HV, 70 mL/kg/h) was at random compared with standard volume (SV, 35 mL/kg/h) CVVH in septic shock patients with acute kidney injury (AKI). PK/PD parameters for all antimicrobial agents used in each patient were studied during five days. RESULTS: Antimicrobial treatment met efficacy targets for both percentage of time above the minimal inhibitory concentration and inhibitory quotient. A significant correlation was observed between the ultrafiltration flow and total systemic clearance (Spearman test: P < 0.005) and between CVVH clearance and drug elimination half-life (Spearman test: P < 0.005). All agents were easily filtered. Mean sieving coefficient ranged from 38.7% to 96.7%. Mean elimination half-life of all agents was significantly shorter during HV-CVVH (from 1.29 to 28.54 h) than during SV-CVVH (from 1.51 to 33.85 h) (P < 0.05). CONCLUSIONS: This study confirms that CVVH influences the PK/PD behavior of most antimicrobial agents. Antimicrobial elimination was directly correlated with convection rate. Current antimicrobial dose recommendations will expose patients to underdosing and increase the risk for treatment failure and development of resistance. Dose recommendations are proposed for some major antibiotic and antifungal treatments in patients receiving at least 25 mL/kg/h CVVH. Sciendo 2019-12-31 /pmc/articles/PMC6985915/ /pubmed/32010602 http://dx.doi.org/10.2478/jtim-2019-0031 Text en © 2019 Dominique Breilh et al., published by Sciendo http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. |
spellingShingle | Original Article Breilh, Dominique Honore, Patrick M. De Bels, David Roberts, Jason A. Gordien, Jean Baptiste Fleureau, Catherine Dewitte, Antoine Coquin, Julien Rozé, Hadrien Perez, Paul Attou, Rachid Redant, Sebastien Kugener, Luc Saux, Marie-Claude Spapen, Herbert D. Ouattara, Alexandre Joannes-Boyau, Olivier Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial |
title | Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial |
title_full | Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial |
title_fullStr | Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial |
title_full_unstemmed | Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial |
title_short | Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial |
title_sort | pharmacokinetics and pharmacodynamics of anti-infective agents during continuous veno-venous hemofiltration in critically ill patients: lessons learned from an ancillary study of the ivoire trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985915/ https://www.ncbi.nlm.nih.gov/pubmed/32010602 http://dx.doi.org/10.2478/jtim-2019-0031 |
work_keys_str_mv | AT breilhdominique pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT honorepatrickm pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT debelsdavid pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT robertsjasona pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT gordienjeanbaptiste pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT fleureaucatherine pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT dewitteantoine pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT coquinjulien pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT rozehadrien pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT perezpaul pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT attourachid pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT redantsebastien pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT kugenerluc pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT sauxmarieclaude pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT spapenherbertd pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT ouattaraalexandre pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT joannesboyauolivier pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial AT pharmacokineticsandpharmacodynamicsofantiinfectiveagentsduringcontinuousvenovenoushemofiltrationincriticallyillpatientslessonslearnedfromanancillarystudyoftheivoiretrial |